Preventive Cardiology | Page 3 of 6 | Links Medicus Content Curation & Alerts in Medicine

In a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, HTG, and low HDL cholesterol levels who received pemafibrate, although TG, VLDL cholesterol, remnant cholesterol, and Apo C-III levels decreased. #AHA22 https://t.co/bNtIAwWTX0 pic.twitter.com/yWaTWarlsv

— NEJM (@NEJM) November 5, 2022

Cohort Study | Pre-eclampsia is associated with increased risk of premature-onset obstructive coronary artery stenosis.

1 Nov, 2022 | 12:02h | UTC

Severity of obstructive coronary artery stenosis after pre-eclampsia – Heart

Primary Care–Based Cardiovascular Disease Risk Management After Adverse Pregnancy Outcomes: a Narrative Review – Journal of General Internal Medicine

Pregnancy Complications and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study – Journal of the American Heart Association

AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk

Consensus statement: Cardiovascular health after menopause transition, pregnancy disorders, and other gynecologic conditions

Cohort Study: Preeclampsia and Cardiovascular Disease

Cohort Study: Cardiovascular Disease After Hypertensive Disorders of Pregnancy Largely Explained by Conventional Cardiovascular Risk Factors

All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease

Gestational Hypertension and Future Risk of Cardiovascular Disease

Research: Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents

M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.

26 Oct, 2022 | 14:32h | UTC

Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis – eClinicalMedicine

Commentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News

Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.

20 Oct, 2022 | 12:25h | UTC

Associations of Hypertriglyceridemia Onset Age With Cardiovascular Disease and All‐Cause Mortality in Adults: A Cohort Study – Journal of the American Heart Association

RCT | Combination of pitavastatin and ezetimibe vs. monotherapy of pitavastatin in patients with primary hypercholesterolemia.

19 Oct, 2022 | 14:15h | UTC

A Multicenter, Randomized, Double-Blind, Active-Controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia – Clinical Therapeutics

Retrospective Cohort Study | Trends in the association between diabetes and cardiovascular events, 1994-2019.

18 Oct, 2022 | 12:58h | UTC

Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 – JAMA (free for a limited period)

Perspective | The polypill: from concept and evidence to implementation.

18 Oct, 2022 | 12:55h | UTC

The polypill: from concept and evidence to implementation – The Lancet (free registration required)

News Release: The polypill could avoid millions of premature deaths, heart attacks and strokes every year, say leading cardiology experts – McMaster University

#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.

#ESCCongress – M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention.

Opinion: A new important study supports wider use of the polypill

#AHA20 – Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

Perspective: Are Polypills and Population-based Treatment the Next Big Things?

The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era

Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population

Randomized Trial: Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases

Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology – Global Heart

Perspective: The Polypill and the Long Journey to Major Impact

Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care

Cohort Study | Purpose in life (Ikigai) and employment status in relation to cardiovascular mortality.

14 Oct, 2022 | 14:06h | UTC

Purpose in life (Ikigai) and employment status in relation to cardiovascular mortality: the Japan Collaborative Cohort Study – BMJ Open

RCT | Allopurinol does not improve outcomes in patients with ischemic heart disease without previous gout.

13 Oct, 2022 | 13:53h | UTC

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial – The Lancet

Invited Commentary: Xanthine oxidase inhibition for cardiovascular disease prevention – The Lancet

Commentary on Twitter

Despite favorable effects on surrogate endpoints in smaller trials, in an RCT trial of 5,721 pts with CAD, allopurinol did not significantly improve cardiovascular prognosis compared to placebo https://t.co/ITW4HAwI2K @TheLancet pic.twitter.com/EggHM8flle

— Pradeep Natarajan (@pnatarajanmd) October 7, 2022

Under a Creative Commons Attribution (CC BY 4.0) License

Calculator | Estimating individual lifetime risk of cardiovascular events in adults with type 2 diabetes.

11 Oct, 2022 | 13:29h | UTC

Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2) – European Journal of Preventive Cardiology

Review | Obesity and contraceptive use: impact on cardiovascular risk.

16 Sep, 2022 | 12:53h | UTC

Obesity and contraceptive use: impact on cardiovascular risk – ESC Heart Failure

News Release: Combined birth control pill linked with increased risk of blood clots in obese women – European Society of Cardiology

Cohort Study | Patients diagnosed with diabetes by oral glucose tolerance test without elevated HbA1c had similar cardiovascular and renal disease risks as those without diabetes.

15 Sep, 2022 | 13:12h | UTC

Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study – Circulation

Commentary: Patients diagnosed by OGTT without elevated HbA1c had similar CV, renal disease risks as those without diabetes – ACP Diabetes

Commentary on Twitter

#OriginalResearch: Oral glucose tolerance test diagnosed #diabetes were not confirmed by HbA1c during 4 year follow-up. Cases without HbA1c confirmation had similar vascular risk as the diabetes-free population. @whitehall2study @MikaKivimaki #AHAJournals https://t.co/ujC8cjRS7S pic.twitter.com/CRR3zlm5x2

— Circulation (@CircAHA) August 30, 2022

Cohort Study | Risk factors for heart disease and stroke are largely similar in men and women globally.

14 Sep, 2022 | 13:18h | UTC

News Release: Risk factors for heart disease and stroke are largely similar in men and women globally, finds study – McMaster University

Original Study: Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

https://twitter.com/TheLancet/status/1569636002762817536

Cohort Study | Prospective associations of daily step counts and intensity with cancer and cardiovascular disease incidence and mortality and all-cause mortality.

14 Sep, 2022 | 13:17h | UTC

Prospective Associations of Daily Step Counts and Intensity With Cancer and Cardiovascular Disease Incidence and Mortality and All-Cause Mortality – JAMA Internal Medicine

Commentaries:

Higher Step Counts Equal Better CV Health: UK Biobank – TCTMD

Pace as important as 10,000 steps for health, finds new research – University of Sidney

How Many Steps a Day (and How Fast) to Lengthen Your Life? – HealthDay

Cohort study showed a possible link between artificial sweeteners and heart disease.

11 Sep, 2022 | 22:55h | UTC

News Release: Possible link between artificial sweeteners and heart disease – BMJ Newsroom

Original Study: Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort – The BMJ

Review/Perspective | European hypertension guideline downgrading of beta-blockers is not justified.

31 Aug, 2022 | 11:51h | UTC

Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified – Blood Pressure

#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.

30 Aug, 2022 | 12:16h | UTC

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials – The Lancet

News Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology

Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD

Consensus Statement | Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis.

30 Aug, 2022 | 12:10h | UTC

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement – European Heart Journal

Commentary on Twitter

Lipoprotein(a) in atherosclerotic CV and aortic stenosis – a European Atherosclerosis Society consensus statement https://t.co/Bzzpd3Bx8M

#EHJ #ESCCongress #ESCYoung @escardio @ehj_ed @rladeiraslopes pic.twitter.com/ZcqaPe581K

— European Society of Cardiology Journals (@ESC_Journals) August 29, 2022

Salt substitutes vs. regular salt: a quick look.

30 Aug, 2022 | 12:02h | UTC

Salt substitutes vs. regular salt: a quick look – Evidently Cochrane

Original Study: Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women – Cochrane Library

Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis – Heart (link to abstract – $ for full-text)

Cluster RCT: A household salt substitution intervention is a cost-effective intervention for preventing stroke and improving quality of life.

#ESCCongress – Cluster RCT: Among patients at increased risk for stroke, salt substitution (75% sodium chloride and 25% potassium chloride by mass) reduced the rates of stroke, major cardiovascular events, and death from any cause.

RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients

Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths

Cluster Randomized Trial: Effect of Salt Substitution on Community-wide Blood Pressure and Hypertension Incidence

Commentary on Twitter

https://twitter.com/CochraneLibrary/status/1563130897159028737

[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.

29 Aug, 2022 | 12:30h | UTC

Evening dosing of blood pressure medication not better than morning dosing – European Society of Cardiology

Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.

29 Aug, 2022 | 12:28h | UTC

Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension

#ESCCongress – RCT | A large study with 46.611 individuals between 65 and 74 years of age found that a comprehensive cardiovascular screening program did not significantly reduce the incidence of death from any cause.

29 Aug, 2022 | 12:24h | UTC

Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Cardiovascular screening may reduce risk of death and cardiovascular disease – European Society of Cardiology

Commentary on Twitter

DANCANVAS: In men age 65-74 years in Denmark, those randomized to invitation to comprehensive screening for subclinical CVD did not have signif reduced all-cause mortality at median 5.6 yrs of follow-up. #ESCCongress https://t.co/YZL87aTVHR pic.twitter.com/HfdiNuU9sK

— NEJM (@NEJM) August 27, 2022

Stay Updated in Your Specialty